Publications
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma KU Leuven
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. KU Leuven
Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma Vrije Universiteit Brussel
BACKGROUND: Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the present case report.
CASE: We report a patient with ACTH-secreting pituitary carcinoma, progressive after multiple lines of therapy including ...
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy KU Leuven
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy University of Antwerp
Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. KU Leuven
Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations KU Leuven
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial KU Leuven
Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors Vrije Universiteit Brussel
INTRODUCTION: Prescribing immune checkpoint inhibitors (ICIs) to cancer patients with an autoimmune disease (AID) is presumed safe when cautious adverse event management is applied. However, guidelines on immunosuppressant (IS) adaptations are limited and real-world evidence is scarce.
METHODS: Current practice of IS adaptations is described in a case series of AID patients treated with ICIs in a tertiary university hospital in ...